Rapport Therapeutics’ RAP-219 meets primary endpoint in Phase 2 bipolar mania trial

Bitget2026/10/20 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rapport Therapeutics announced positive Phase 2 results for RAP-219 in acute bipolar mania, meeting primary and secondary endpoints.
Treatment significantly improved manic symptoms versus placebo; all treatment-emergent adverse events were mild or moderate, with no serious adverse events.
An FDA meeting is planned for the first quarter of 2027; two Phase 3 trials are expected in the second half.
Additional Phase 2 results, including post-treatment safety data, will be presented at a future medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200600PRIMZONEFULLFEED9849210) on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rapport Therapeutics’ RAP-219 meets primary endpoint in Phase 2 bipolar mania trial

You may also like

Crypto prices